Direct oral anticoagulants in rare venous thrombosis.

Link to article at PubMed

Related Articles

Direct oral anticoagulants in rare venous thrombosis.

Intern Emerg Med. 2016 Feb 13;

Authors: Finazzi G, Ageno W

The direct inhibitors of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently used in patients with venous thrombosis of the lower or upper limbs or with pulmonary embolism. However, the use of these direct oral anticoagulants (DOACs) in subjects with abdominal or cerebral venous thrombosis is more contentious due to the paucity of available data. In a few case reports and small series of patients hitherto published, the DOACs showed good efficacy and safety, supporting an extension of their use to these rare conditions. Thus, prospective cohort studies and randomized controlled trials have been set up. In this article, we review the published clinical experience with DOACs in rare venous thrombosis, and provide updated information on ongoing clinical trials.

PMID: 26875179 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.